Drug Trial Radar · NCT03065400
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Last checked: Nov 20, 2026Latest source record: Jun 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 14, 2017
Primary completion
May 28, 2020
Study completion May 28, 2020
Sponsor
- Lead sponsor
- John MascarenhasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Massachusetts General Hospital; Montefiore Medical Center
- First posted
- Feb 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase (MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of the bone marrow in which excessive cells are produced. Pembrolizumab also known as Keytruda is a drug that has recently been approved in the United Stated by the Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma and disease progression. Pembrolizumab is experimental in the treatment of MPN. The researchers want to find out what effects, good and /or bad it has on participants and the disease. Participants qualify to take part in this research study if have been diagnosed with a MPN blood disorder called myelofibrosis (MF). Accelerated (10-19% blasts in the blood or bone marrow) and blast phase (\>20% blasts in the blood or bone marrow) MPN has been a difficult disease to treat. The term "blasts" refers to immature cells found in the bone marrow. They are not fully developed, and therefore, do not yet carry out any particular function within the body. Funds for conducting this research are provided by Merck and Company, the manufacturer of the study drug pembrolizumab.
Conditions
- Chronic Phase Myelofibrosis
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Polycythemia Vera
Interventions
PembrolizumabDrug
200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- European Leukemia Net -International Working Group (ELN-IWG) CriteriaTime frame: 18 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Harvard Medical School Massachusetts General Hospital
Boston, Massachusetts
Icahn School of Medicine at Mount Sinai
New York, New York
Montefiore Medical Center Division of Hematology, Department of Oncology
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.